GlassScriptPhysician profile
Dana E Free
NPI 1164855136
$3,956.38
in general payments reported to CMS, 2019-2025
23 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.51 · 2022: $481 · 2023: $930 · 2024: $1,065 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $727.90 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $511.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $408.24 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $220.99 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $210.77 | 2024-2025 | Rexulti |
| Amgen INC. | $132.80 | 2023 | Repatha, Otezla |
| Corcept Therapeutics | $99.84 | 2024-2025 | Korlym |
| Atland Pharmaceuticals, LLC | $96.25 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Corium, LLC | $82.04 | 2023-2025 | Azstarys |
| Astellas Pharma US INC | $48.07 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.39 | 2023-2025 | Relistor, Xifaxan |
| Sanofi Pasteur INC. | $39.95 | 2022-2023 | |
| Abbott Laboratories | $37.53 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $37.37 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $29.50 | 2023 | Contrave, Nexlizet, Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $28.51 | 2022 | |
| Ucb, INC. | $27.81 | 2025 | Briviact |
| Medline Industries LP | $22.23 | 2025 | |
| Sobi, INC | $21.33 | 2022 | |
| Exact Sciences Corporation | $15.29 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $14.61 | 2023 | |
| Axsome Therapeutics, INC. | $14.03 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Free listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.